Skip to main content

Read more about our corporate brand here.

Search
Search
Reports

The Future of Healthtech 2026

Megan Scheffel, Adam Tweedy, Dennis He, Matt Donne, Ph.D., Alex Lennox-Miller, Urbashee Paul, Ph.D., Josh Pherigo
November 09, 2026

Key takeaways

Healthtech is everywhere—and in 2026, it's being put to the test. Capital is still flowing, but investors want proof that products improve outcomes or lower costs. This healthtech report draws on our proprietary research to reveal where healthtech and digital health funding is moving and what AI is really worth.

64%

Valuation premium for early-stage AI healthtech companies over non-AI peers

Late-stage AI companies experience a 52% valuation premium.

$74M

Median pre-money valuations among late-stage companies

Late-stage valuations climbed 63% this year as investors focus on mature companies with proven effectiveness.

47%

Of 2026 healthtech funding went to $100M+ rounds

Only 3% of deals drove nearly half of funding, with giga-rounds hitting the highest share ever (12%).

Behind the data

The numbers behind the takeaways tell a deeper story. Here’s what the data reveals about healthtech investment, the climb in late-stage deal sizes and the return of giga-rounds.

Value-based care

Value-based care valuations and VC reach new heights

Investment in clinical value-based care is projected to reach $2.3 billion in 2026—the most since 2021—with median valuations spiking to $100 million.

Investors are pouring capital into companies that can demonstrate outcomes and savings in a matter of months, rewarding proven effectiveness over promise.

Bar chart and line graph showing annual capital invested and median pre-money valuations in value-based care and management services from 2020 to 2026. Notes: Includes 12 value-based care (VBC) and management service deals with disclosed pre-money valuations Sources: PitchBook Data, Inc. and First Citizens Innovation Banking analysis.
Valuations

Early- and late-stage healthtech valuations hit new highs

Median early-stage pre-money valuations have risen 130% to $46 million since 2020, the largest jump across stages.

Seed valuations have nearly doubled since 2020, yet seed deals reflect a quarter of all deals and 5% of capital, a gap that underscores how funding concentrates around maturity and traction.

Chart showing median pre-money valuations of seed, early-stage and late-stage companies from 2020 to Q3 2026 Notes: Only includes rounds that disclose a pre-money valuation count. Sources: PitchBook Data, Inc. and First Citizens Innovation Banking analysis.
Deal size

The giga-round is back and bigger than ever

Rounds of $500 million or more accounted for 12% of healthtech venture capital this year, the highest ratio on record, after 2 years with none at all.

Neko Health, WHOOP and Alan led the giga-round comeback, as investors directed record capital into a small group of established winners.

Chart showing the share of health tech VC capital invested by round size, 2020 to Q3 2026 Notes: Rounds of $500M or more are defined as giga-rounds; mega-rounds are $100M up to $500M. Source: PitchBook Data, Inc. and First Citizens Innovation Banking analysis.

Read the full Future of Healthtech report

More about the authors

Megan Scheffel

Megan Scheffel

Head of Life Science and Healthcare

Adam Tweedy
Life Science and Healthcare

Adam Tweedy

Head of Investor Coverage

Dennis He
Life Science

Dennis He

Managing Director

Matt Donne, Ph.D.
Life Science and Healthcare Venture Capital Relationship Management

Matt Donne, Ph.D.

Managing Director

Alex Lennox-Miller
Market Insights

Alex Lennox-Miller

Senior Researcher

Urbashee Paul, Ph.D.
Market Insights

Urbashee Paul, Ph.D.

Researcher

Josh Pherigo
Market Insights

Josh Pherigo

Principal Researcher


Explore other reports

Healthcare Industry Trends Reports
Read Report Report

Healthcare Industry Trends

Megan Scheffel, Adam Tweedy, Dennis He, Matt Donne, Alex Lennox-Miller, Josh Pherigo, Urbashee Paul

Innovation in Women's Health Reports
Read Report Report

Innovation in Women's Health

Megan Scheffel, Adam Tweedy, Nina Kandilian, Alex Lennox-Miller, Josh Pherigo, Urbashee Paul

State of the VC-Backed CFO 2026 Reports
Read Report Report

State of the VC-Backed CFO 2026

Jennifer Friel Goldstein, Emily Gonsenheim, Josh Pherigo, Eli Oftedal, Andrew Pardo


This material is for informational purposes only and is not intended to be an offer, specific investment strategy, recommendation, or solicitation to purchase or sell any security or insurance product, and should not be construed as legal, tax, or accounting advice. Please consult with your legal or tax advisor regarding the particular facts and circumstances of your situation prior to making any financial decision. While we believe that the information presented is from reliable sources, we do not represent, warrant, or guarantee that it is accurate or complete.

All third-party trademarks referenced by First Citizens Bank remain the property of their respective owners. First Citizens Bank’s use of third-party trademarks does not indicate any relationship, sponsorship or endorsement between First Citizens Bank and the owners of these trademarks. All references by First Citizens Bank to third-party trademarks are to identify the corresponding third-party goods and services and intended to constitute nominative fair use under applicable trademark laws.

Investment and insurance products are not a deposit, not FDIC-insured, not guaranteed by First Citizens, not insured by any federal government agency and may lose value.

Back to top
You are now leaving First Citizens Innovation Banking

You will be directed to a different website or mobile app that has its own terms of use, visitor agreement, security and privacy policies. First Citizens Innovation Banking is not responsible for (and does not provide) any products, services or content at the third party site or app, except for the products and services that carry the First Citizens Innovation Banking name.